Is Intrauterine Infusion Before Embryo Transfer Necessary?

Start with the conclusion: it is not for everyone

Intrauterine infusion is an option to discuss only when there is a plausible indication. It is not a routine step before every embryo transfer.

Patients having a first transfer, with normal endometrial thickness and pattern, no obvious uterine cavity abnormality and reasonable embryo quality, usually do not need infusion just to feel that something extra was done.

For most people, the key drivers remain embryo potential, endometrial preparation, uterine structure, luteal support, transfer timing and laboratory quality. Only selected situations, such as carefully evaluated recurrent implantation failure, repeated thin endometrium or poor repair after uterine injury, enter individualized discussion.

The 2023 ESHRE recommendations on RIF warn against reducing RIF to a fixed number of failed transfers. Age, embryo potential, embryo number and quality, genetic testing and uterine factors all matter.

Practical judgment: infusion is not a bonus step before transfer. It is a supplementary option only when there is a defined problem. Without that problem, more intervention may add cost, delay and anxiety without clear benefit.

What it is: improving the local environment, not pushing the embryo into the lining

The procedure aims to influence the uterine cavity or endometrium. It does not replace embryo transfer.

Intrauterine infusion means placing medication, cytokines or an autologous blood component into the uterine cavity through a thin catheter before embryo transfer. The goal is to improve the local endometrial environment.

PRP, G-CSF and hCG are based on different biological hypotheses. Evidence from one cannot be automatically applied to another. A thicker lining also does not automatically mean a higher live-birth rate.

Failed transfer is multifactorial: do not blame the lining too early

Implantation is a complex handoff. The endometrium is only one part of it.

After a failed transfer, it is understandable to wonder whether the lining was the problem. The endometrium is visible and measurable. But one or two failures do not automatically prove an endometrial issue.

Embryo developmental potential comes first. A good-looking embryo may still be chromosomally abnormal. Age, egg and sperm quality and culture conditions all influence embryo competence. Endometrial thickness, pattern, blood flow, inflammation, structure, luteal support, transfer timing and uterine contractions also matter.

The risk is using infusion as a default rescue after failure. If embryos, uterine structure, chronic endometritis, endometrial preparation and luteal support have not been reviewed, infusion may turn a complex problem into an anxiety-driven add-on.

Before discussing infusion, finish the basic work-up

Check the foundation before adding fertilizer.

A responsible sequence is to identify and treat underlying issues first. Infusion should not replace hysteroscopy when indicated, inflammation treatment, hydrosalpinx management, adjustment of endometrial preparation or embryo quality review.

• Embryo level: repeated transfer of good-quality embryos; whether chromosomal risk has been assessed; repeated poor development or few usable embryos.
• Uterine cavity: polyps, adhesions, submucosal fibroids, cavity fluid or reflux from hydrosalpinx.
• Endometrial status: repeated thin lining, poor pattern, interrupted endometrial line, poor blood flow or poor repair on hysteroscopy.
• Inflammation and infection: suspected chronic endometritis, repeated intrauterine procedures, infection history or abnormal bleeding.
• Endocrine and support: thyroid, prolactin, glucose, weight, luteal support and progesterone exposure matched to transfer timing.

Visible causes should be managed directly. Infusion may support the local environment, but it cannot erase an untreated root cause.

Three groups where discussion may be reasonable

Three situations where it is usually not necessary

If the only explanation is “everyone does it” or “it cannot hurt,” pause. A useful add-on should have a patient-specific reason.

PRP, G-CSF and hCG: evidence boundaries

All three approaches aim to improve the local endometrial environment, but they are not the same intervention. A cautious statement is appropriate: some selected patients may discuss them; they should not be presented as routine or guaranteed to improve success.

Simple does not mean casual

Intrauterine infusion is often outpatient, but it is still an intrauterine procedure.

A thin catheter is usually passed through the cervix and the solution is slowly infused. Some protocols use a specific day in the preparation cycle or repeat the procedure once or twice.

Any intrauterine procedure before transfer should follow sterile practice and should not disturb endometrial preparation or the transfer window.

• Procedure risks: pain, minor bleeding, infection, cervical stimulation, vasovagal symptoms and very rare instrument-related injury.
• Medication or product risks: allergy, drug reaction, contamination or unstable PRP preparation quality.
• Cognitive risk: treating an uncertain add-on as proven therapy may increase cost, delay and disappointment while hiding the real problem.
• After the procedure: fever, significant abdominal pain, abnormal discharge or persistent bleeding should prompt medical care.

Ten questions to ask your doctor

A good plan can withstand specific questions.

• Why do I need this? Is it for thin endometrium, poor repair, RIF or another issue?
• Have uterine cavity problems, hydrosalpinx and chronic endometritis been checked or treated?
• Are we using PRP, G-CSF or hCG, and why this one?
• What outcome is expected: thickness, pattern, blood flow, clinical pregnancy or live birth?
• How strong is the evidence for patients like me? Do any guidelines support routine use?
• If I do not do it, will this transfer clearly be affected?
• When will it be done, and could it affect endometrial preparation or the transfer window?
• How many times is it needed, and how will we decide whether to continue?
• What are the adverse effects, infection risk, cost and alternatives?
• Is this experimental or exploratory, and will there be written informed consent?

These questions are not confrontational. They turn “let us try” into “let us try for a reason.”

A practical decision path

The decision is a balance of benefit, risk and timing.

Explaining the reason is more professional than adding one more step

Intrauterine infusion is neither a miracle nor worthless. Its proper role is selected, patient-specific and evidence-bounded discussion.

Patients do not need to panic because others did it, nor accept it automatically because it is suggested. What you need is a clear explanation of the problem, the target, the evidence, risks, cost and alternatives.

For clinics and clinicians, professionalism is not doing more procedures. It is making each step more justified and communicating uncertainty honestly.

Summary: intrauterine infusion is not a standard step before transfer. It is an option for a minority of patients, depending on indication, work-up and evidence boundaries.